

February 7, 2024

Pharma Haven Currencies

Local pharmaceutical industries underpin much of DKK and CHF

- Pharma plays disproportionately large role in Danish, Swiss economies
- Pharma-related fiscal, trade and capital flows material for currencies
- US BAT would materially damage terms of trade for pharma producers

Success brings monetary and political headaches

Currency pegs, currency boards or exchange-rate targets rarely set pulses racing in FX markets – unless there is a chance of abandonment. Most emerging markets have scrapped such mechanisms. Over the last 15 years, incidents of note have largely been in developed markets, with central banks of surplus nations trying to prevent currency appreciation. The Swiss franc and Czech koruna have been the best examples of such forms of extraordinary monetary policy, but we doubt they will be revisited barring extreme circumstances.


Over the past two years, however, the Danish krone has been attracting particular attention due to esoteric developments. The success of one pharmaceutical company and demand for its products has led to severe distortions in the local economy, with ramifications for monetary and fiscal policy. It has been well documented that the market capitalisation of the company itself is larger than the country's GDP – though this is a secondary matter as it is comparing a 'stock' (market capitalisation) concept to a flow (GDP) concept. However, the Danish government has acknowledged that the pharmaceutical industry is now so large in the country that it is necessary to separate the sector from the rest of the economy. This is not unlike how Norway needs to separate its onshore and offshore economies to account for the outsized impact of its energy industry, the export revenues of which also play a pivotal role in the formation of monetary, exchange-rate and fiscal policy in the country.

Subtracting the pharmaceutical industry, Denmark's industrial production would have been in

Domestic Product and 50% of total exports. As exhibit 2 shows, without the pharmaceutical industry the country would be running a rather large trade deficit.

Compared to Denmark, the Swiss pharmaceutical industry's support for the franc is far more through the current account side, and with a flexible exchange rate these earnings can be directly or indirectly recycled overseas to capture higher yields. Under normal circumstances, the Swiss reaction function is not dissimilar to that of savings-heavy Asian exporters, though discretion and execution is largely driven by the private sector, rather than reliant on state-related actors such as reserve managers or sovereign wealth funds.

Exhibit #2: Swiss Trade Balance Breakdown




Source: Macrobond, BNY Mellon

Problems usually arise when the external yield and risk environment is no longer conducive to outflows and these savings stay onshore. The best example was during the Eurozone sovereign debt crisis, when the very existence of the euro was called into question. While the SNB's actions attracted significant attention, there have been periods of stress for DKK, as well. The DNB was forced into negative deposit rates for much of the zero-rate era, along with the SNB. Exhibit 3 illustrates that even during the most recent round of inflation-target and positive rates, both the DNB and SNB have been forced to keep their respective deposit rates below the ECB's benchmark. In the DNB's case, the sudden surge in pharmaceutical-related flows has resulted in a wider corridor between it and the ECB. The need to maintain respective currency arrangements have forced the Swiss and Danish central banks into what is probably a far more dovish interest-rate position than might be preferred.

The SNB has the option of allowing strong franc appreciation to tighten financial conditions,

whereas in Denmark's case strong macroprudential management – led by its unique mortgage market – and fiscal restraint will likely be the conventional levers to prevent overheating driven by low real rates and the lack of a currency offset. When manufacturing or even general export receipts are strong and competitiveness through the wage channel is a risk, self-imposed restraint is the only way to limit REER gains and competitiveness losses. This is especially true for pharmaceutical-related currencies, as patent protections mean that revenue streams can be maintained for an extended period.


Exhibit #3: Deposit Rate Paths



Source: Bloomberg, BNY Mellon

We do, however, see one significant non-health-related challenge to pharmaceutical havens. For both Denmark and Switzerland, the US is the largest non-European export market (exhibit 4). The Swiss pharmaceutical industry is particularly dependent on sales to the US, and the same will likely materialise for Denmark given that its recent pharmaceutical innovations are particularly in demand across the Atlantic.

Exhibit #4: Exports To US, Share Of Total



Source: Bloomberg, BNY Mellon* based on rolling 12m exports

Burgeoning pharmaceutical-related surpluses seem sure to attract political attention. Switzerland has been mentioned in the US Treasury’s Currency Manipulation report in the past. Currency boards or pegs such as Denmark’s are also ripe targets, even though there is a very long history of currency links between Denmark and Germany out of economic necessity. Even without placing too much emphasis on the result of the US election later this year (November), trade barriers remain on the advance globally, and it is possible that a border-adjustment tax (BAT) for manufactured goods will be back on the agenda. If tax arrangements for goods produced outside of but destined for the US are subject to preferential tax treatment, a BAT levied on such goods would effectively impose REER appreciation on the exporting country’s currency.

The pharmaceutical prowess of Denmark and Switzerland has played an instrumental role in global demand for their currencies and should be celebrated. However, monetary side effects and political complications are never far away in the modern world. Both countries’ governments and monetary authorities will continue to have their work cut out to strike the right balance and prevent distortions from generating serious damage to their economies.

Please direct questions or comments to: iFlow@BNYMellon.com



Geoff Yu
EMEA MACRO STRATEGIST

CONTACT GEOFF



bnymellon.com

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may be used as a generic term to reference the corporation as a whole and/or its various subsidiaries generally. This material and any products and services may be issued or provided under various brand names in various countries by duly authorized and regulated subsidiaries, affiliates, and joint ventures of BNY Mellon, which may include any of the following. The Bank of New York Mellon, at 225 Liberty St, NY, NY USA, 10286, a banking corporation organized pursuant to the laws of the State of New York, and operating in England through its branch at One Canada Square, London E14 5AL, UK, registered in England and Wales with numbers FC005522 and BR000818. The Bank of New York Mellon is supervised and regulated by the New York State Department of Financial Services and the US Federal Reserve and authorized by the Prudential Regulation Authority. The Bank of New York Mellon, London Branch is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. The Bank of New York Mellon SA/NV, a Belgian public limited liability company, with company number 0806.743.159, whose registered office is at 46 Rue Montoyerstraat, B-1000 Brussels, Belgium, authorized and regulated as a significant credit institution by the European Central Bank (ECB), under the prudential supervision of the National Bank of Belgium (NBB) and under the supervision of the Belgian Financial Services and Markets Authority (FSMA) for conduct of business rules, and a subsidiary of The Bank of New York Mellon. The Bank of New York Mellon SA/NV operates in England through its branch at 160 Queen Victoria Street, London EC4V 4LA, UK, registered in England and Wales with numbers FC029379 and BR014361. The Bank of New York Mellon SA/NV (London Branch) is authorized by the ECB and subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request. The Bank of New York Mellon SA/NV operating in Ireland through its branch at 4th Floor Hanover Building, Windmill Lane, Dublin 2, Ireland trading as The Bank of New York Mellon SA/NV, Dublin Branch, is authorised by the ECB and is registered with the Companies Registration Office in Ireland No. 907126 & with VAT No. IE 9578054E. The Bank of New York Mellon, Singapore Branch, subject to regulation by the Monetary Authority of Singapore. The Bank of New York Mellon, Hong Kong Branch, subject to regulation by the Hong Kong Monetary Authority and the Securities & Futures Commission of Hong Kong. If this material is distributed in Japan, it is distributed by The Bank of New York Mellon Securities Company Japan Ltd, as intermediary for The Bank of New York Mellon. If this material is distributed in, or from, the Dubai International Financial Centre ("DIFC"), it is communicated by The Bank of New York Mellon, DIFC Branch, regulated by the DFSA and located at DIFC, The Exchange Building 5 North, Level 6, Room 601, P.O. Box 506723, Dubai, UAE, on behalf of The Bank of New York Mellon, which is a wholly-owned subsidiary of The Bank of New York Mellon Corporation. This material is intended for Professional Clients only and no other person should act upon it. Not all products and services are offered in all countries.

The information contained in this material is intended for use by wholesale/professional clients or the equivalent only and is not intended for use by retail clients. If distributed in the UK, this material is a financial promotion.

This material, which may be considered advertising, is for general information purposes only and is not intended to provide legal, tax, accounting, investment, financial or other professional advice on any matter. This material does not constitute a recommendation by BNY Mellon of any kind. Use of our products and services is subject to various regulations and regulatory oversight. You should discuss this material with appropriate advisors in the context of your circumstances before acting in any manner on this material or agreeing to use any of the referenced products or services and make your own independent assessment (based on such advice) as to whether the referenced products or services are appropriate or suitable for you. This material may not be comprehensive or up to date and there is no undertaking as to the accuracy, timeliness, completeness or fitness for a particular purpose of information given. BNY Mellon will not be responsible for updating any information contained within this material and opinions and information contained herein are subject to change without notice. BNY Mellon assumes no direct or consequential liability for any errors in or reliance upon this material.

This material may not be distributed or used for the purpose of providing any referenced products or services or making any offers or solicitations in any jurisdiction or in any circumstances in which such products, services, offers or solicitations are unlawful or not authorized, or where there would be, by virtue of such distribution, new or additional registration requirements.

The terms of any products or services provided by BNY Mellon to a client, including without limitation any administrative, valuation, trade execution or other services shall be solely determined by the definitive agreement relating to such products or services. Any products or services provided by BNY Mellon shall not be deemed to have been provided as fiduciary or adviser except as expressly provided in such definitive agreement. BNY Mellon may enter into a foreign exchange transaction, derivative transaction or collateral arrangement as a counterparty to a client, and its rights as counterparty or secured party under the applicable transactional agreement or collateral arrangement shall take precedence over any obligation it may have as fiduciary or adviser or as service provider under any other agreement.

Pursuant to Title VII of The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the applicable rules thereunder, The Bank of New York Mellon is provisionally registered as a swap dealer with the Commodity Futures Trading Commission ("CFTC") and is a swap dealer member of the National Futures Association (NFA ID 0420990).

BNY Mellon (including its broker-dealer affiliates) may have long or short positions in any currency, derivative or instrument discussed herein. BNY Mellon has included data in this material from information generally available to the public from sources believed to be reliable. Any price or other data used for illustrative purposes may not reflect actual current conditions. No representations or warranties are made, and BNY Mellon assumes no liability, as to the suitability of any products and services described herein for any particular purpose or the accuracy or completeness of any information or data contained in this material. Price and other data are subject to change at any time without notice.

Rates: neither BNY Mellon nor any other third party provider shall be liable for any errors in or delays in providing or making available the data (including rates, WM/Reuters Intra-Day Spot Rates and WM/Reuters Intra-Day Forward Rates) contained within this service or for any actions taken in reliance on the same, except to the extent that the same is directly caused by its or its employees' negligence. The WM/Reuters Intra-Day Spot Rates and WM/Reuters Intra-Day Forward Rates are provided by The World Markets Company plc ("WM") in conjunction with Reuters. WM shall not be liable for any errors in or delays in providing or making available the data contained within this service or for any actions taken in reliance on the same, except to the extent that the same is directly caused by its or its employees' negligence.

The products and services described herein may contain or include certain "forecast" statements that may reflect possible future events based on current expectations. Forecast statements are neither historical facts nor assurances of future performance. Forecast statements typically include, and are not limited to, words such as "anticipate", "believe", "estimate", "expect", "future", "intend", "likely", "may", "plan", "project", "should", "will", or other similar terminology and should NOT be relied upon as accurate indications of future performance or events. Because forecast statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. iFlow® is a registered trademark of The Bank of New York Mellon Corporation under the laws of the United States of America and other countries.

This document is intended for private circulation. Persons accessing, or reading, this material are required to inform themselves about and to observe any restrictions that apply to the distribution of this information in their jurisdiction.

Currency Administration is provided under and subject to the terms of a definitive agreement between BNY Mellon and the client. BNY Mellon exercises no investment discretion thereunder, but acts solely pursuant to the instructions in such agreement or otherwise provided by the client. Unless provided by definitive agreement, BNY Mellon is not an agent or fiduciary thereunder, and acts solely as principal in connection with related foreign exchange transactions.

All references to dollars are in US dollars unless specified otherwise.

This material may not be reproduced or disseminated in any form without the prior written permission of BNY Mellon. Trademarks, logos and other intellectual property marks belong to their respective owners.

The Bank of New York Mellon, member FDIC.

© 2020 The Bank of New York Mellon Corporation. All rights reserved.